Terns Pharmaceuticals, Inc.

NasdaqGS TERN

Terns Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.00

Terns Pharmaceuticals, Inc. Debt to Equity Ratio is 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a -32.27% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Terns Pharmaceuticals, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.00.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGS: TERN

Terns Pharmaceuticals, Inc.

CEO	Ms. Amy L. Burroughs M.B.A.
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	1065 East Hillsdale Boulevard
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Key trends

Past 5 years